<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="EN" dtd-version="1.4"><!--The publisher of this article does not allow downloading of the full text in XML form.--><front><journal-meta><journal-id journal-id-type="nlm-ta">Antimicrob Agents Chemother</journal-id><journal-id journal-id-type="pmc-domain-id">82</journal-id><journal-id journal-id-type="pmc-domain">aac</journal-id><journal-id journal-id-type="publisher-id">aac</journal-id><journal-title-group><journal-title>Antimicrobial Agents and Chemotherapy</journal-title></journal-title-group><issn pub-type="ppub">0066-4804</issn><issn pub-type="epub">1098-6596</issn><publisher><publisher-name>American Society for Microbiology (ASM)</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC149016</article-id><article-id pub-id-type="pmcid-ver">PMC149016.1</article-id><article-id pub-id-type="pmcaid">149016</article-id><article-id pub-id-type="pmcaiid">149016</article-id><article-id pub-id-type="pmid">12499181</article-id><article-id pub-id-type="doi">10.1128/AAC.47.1.138-143.2003</article-id><article-id pub-id-type="publisher-id">0568</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Experimental Therapeutics</subject></subj-group></article-categories><title-group><article-title>Modeling of Transfer Kinetics at the Serum-Cerebrospinal Fluid Barrier in Rabbits with Experimental Meningitis: Application to Grepafloxacin</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Pfister</surname><given-names initials="M">Marc</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="cor1">*</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Zhang</surname><given-names initials="L">Liping</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Hammarlund-Udenaes</surname><given-names initials="M">Margareta</given-names></name><xref ref-type="aff" rid="aff1">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Sheiner</surname><given-names initials="LB">Lewis B.</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Gerber</surname><given-names initials="CM">Cynthia M.</given-names></name><xref ref-type="aff" rid="aff1">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>T&#228;uber</surname><given-names initials="MG">Martin G.</given-names></name><xref ref-type="aff" rid="aff1">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Cottagnoud</surname><given-names initials="P">Philippe</given-names></name><xref ref-type="aff" rid="aff1">3</xref></contrib></contrib-group><aff id="aff1">Department of Laboratory Medicine and Biopharmaceutical Sciences, University of California, San Francisco, California,<label>1</label> Department of Medicine,<label>3</label> Institute of Microbiology and Infectious Diseases, Inselspital, University of Berne, Berne, Switzerland,<label>4</label> Department of Pharmaceutical Biosciences, Division of Pharmacokinetics and Drug Therapy, University of Uppsala, Uppsala, Sweden<label>2</label></aff><author-notes><fn id="cor1"><label>*</label><p>Corresponding author. Mailing address: Box 0626, UCSF, 521 Parnassus Ave., San Francisco, CA 94143-0626. Phone: (415) 502-1989. Fax: (415) 476-2796. E-mail: <email>marc@c255.ucsf.edu</email>.</p></fn></author-notes><pub-date pub-type="ppub"><month>1</month><year>2003</year></pub-date><volume>47</volume><issue>1</issue><issue-id pub-id-type="pmc-issue-id">4500</issue-id><fpage>138</fpage><lpage>143</lpage><history><date date-type="received"><day>11</day><month>6</month><year>2001</year></date><date date-type="rev-recd"><day>26</day><month>2</month><year>2002</year></date><date date-type="accepted"><day>24</day><month>9</month><year>2002</year></date></history><pub-history><event event-type="pmc-release"><date><day>01</day><month>01</month><year>2003</year></date></event><event event-type="pmc-live"><date><day>02</day><month>04</month><year>2003</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2014-10-27 17:50:49.157"><day>27</day><month>10</month><year>2014</year></date></event></pub-history><permissions><copyright-statement>Copyright &#169; 2003, American Society for Microbiology</copyright-statement><copyright-year>2003</copyright-year></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="0568.pdf"/><abstract><p>The goals of the present study were to model the population kinetics of in vivo influx and efflux processes of grepafloxacin at the serum-cerebrospinal fluid (CSF) barrier and to propose a simulation-based approach to optimize the design of dose-finding trials in the meningitis rabbit model. Twenty-nine rabbits with pneumococcal meningitis receiving grepafloxacin at 15 mg/kg of body weight (intravenous administration at 0 h), 30 mg/kg (at 0 h), or 50 mg/kg twice (at 0 and 4 h) were studied. A three-compartment population pharmacokinetic model was fit to the data with the program NONMEM (Nonlinear Mixed Effects Modeling). Passive diffusion clearance (CL<sub>diff</sub>) and active efflux clearance (CL<sub>active</sub>) are transfer kinetic modeling parameters. Influx clearance is assumed to be equal to CL<sub>diff</sub>, and efflux clearance is the sum of CL<sub>diff</sub>, CL<sub>active</sub>, and bulk flow clearance (CL<sub>bulk</sub>). The average influx clearance for the population was 0.0055 ml/min (interindividual variability, 17%). Passive diffusion clearance was greater in rabbits receiving grepafloxacin at 15 mg/kg than in those treated with higher doses (0.0088 versus 0.0034 ml/min). Assuming a CL<sub>bulk</sub> of 0.01 ml/min, CL<sub>active</sub> was estimated to be 0.017 ml/min (11%), and clearance by total efflux was estimated to be 0.032 ml/min. The population kinetic model allows not only to quantify in vivo efflux and influx mechanisms at the serum-CSF barrier but also to analyze the effects of different dose regimens on transfer kinetic parameters in the rabbit meningitis model. The modeling-based approach also provides a tool for the simulation and prediction of various outcomes in which researchers might be interested, which is of great potential in designing dose-finding trials.</p></abstract><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front></article></pmc-articleset>